ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company
Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services
ELC Group, a provider of regulatory affairs services, has been awarded a €1.5m contract by one of China’s biggest pharmaceutical companies.
The company says winning the contract is a major endorsement of its Concept to Commercialisation approach, which delivers an integrated portfolio of regulatory affairs consultancy services to customers, from the development stage to clinical trials, completion of product registration, and successful marketing of the product.
The major project, which will see two products taken through ELC Group’s end-to-end service, is expected to be complete by the end of 2016. The customer, whose name is not revealed, is a top 25 Chinese pharmaceutical company and is an active ingredients company that is moving towards the finished formulation business.
ELC Group was selected for the contract following a rigorous qualification process, which compared the company against a number of other domestic and international clinical research organisations (CROs).
ELC Group CEO Marco Rubinstein said: 'This landmark contract award marks an exciting new level for us, both in size and scope of projects.'